Dysfunction of Gα q/11 is a characteristic feature of AD patients and transgenic mice with ADlike symptoms (see accompanying manuscript and references [1] [2] [3] [4] [5] . The Gα q/11 -protein defect is a well-established hallmark of clinicial AD (5) . However, the pathophysiological role of the G-protein defect is barely understood. A direct relationship between Gα q/11 dysfunction and the pathogenesis of AD leading to neurodegeneration and dementia is suggested by the important role of Gα q/11 proteins in neuronal survival and memory (6, 7) . In addition, many of the cognition-enhancing effects of acetylcholine are mediated by the Gα q/11 -coupled muscarinic receptors (8) . The M 1 receptor is a major target of Gα q/11 dysfunction of AD patients and mice, and impaired Gα q/11 -coupling of M 1 receptors correlates with disease severity (5) .
To better understand the pathophysiological function of the G-protein defect in AD, we analyzed the mechanism accounting for the G-protein defect in AD. In the first manuscript we identified cross-linked AT 2 receptor oligomers in brain of AD patients and transgenic mice with AD-like symptoms. Co-enrichment studies showed that AT 2 2 receptor oligomers resembled dominantnegative receptors by sequestering Gα q/11 in the absence of agonist. The cross-linked AT 2 receptors were directly linked to the progression of AD because (aggregated) amyloid β (Aβ) triggered AT 2 oligomerization in vivo in a dose-dependent manner by a twostep process of oxidative and transglutaminasedependent cross-linking. Down-regulation of AT 2 receptors by RNA interference revealed that AT 2 receptor (oligomers) contributed to Gα q/11 dysfunction of transgenic mice with AD-like symptoms. Specifically, AT 2 receptor oligomers impaired signaling of Gα q/11 -coupled muscarinic M 1 receptors in the hippocampus.
Because activation of hippocampal Gα q/11 -stimulated signaling retards the development of AD-like symptoms in transgenic mice (9), we thought that AT 2 receptor oligomers were directly involved in symptoms of neurodegeneration. To address this question we used an AT 2 receptor mutant to suppress AT 2 oligomerization in vitro and in vivo. We present here that inhibition of AT 2 oligomerization by stereotactic expression of a mutated AT 2 receptor retarded the development of neurodegenerative symptoms in the hippocampus of transgenic mice with AD-like pathology. These observations provide strong evidence for an involvement of AT 2 oligomers in mediating symptoms of neurodegeneration.
EXPERIMENTAL PROCEDURES
Cell culture, protein expression and functional assays-Cultivation of human embryonic kidney (HEK) cells, and transfection with plasmids encoding AT 2 , AT 2 ΔCTer , M 1 , Gα 11 Q209L , or transglutaminase-2 under control of the CMV promoter was performed as described (10, 11) . Reactive oxygen species (ROS) was induced by expression of NOX-3. Changes in total inositol phosphates and measurement of [Ca 2+ ] i were determined with intact cells (11, 12 Immuno-affinity enrichment of Gα q/11 followed by immunoblot detection of coenriched AT 2 was performed by a method that was described (12) .
Quantification of the carbacholstimulated M 1 -Gα q interaction in the presence of increasing levels of oligomeric AT 2 (0 -300 fmol/mg protein) was performed after immuno-affinity enrichment of M 1 receptors from M 1 receptor-expressing HEK cells (~900 fmol/mg protein) co-expressing oligomeric AT 2 as indicated. Briefly, HEK cell membranes (50 µg/point) in GTP-free buffer supplemented with 2 mM MgCl 2 were incubated in the absence or presence of 1 mM carbachol for 60 min at 12 °C followed by 20 min at 24 °C and the addition of 1 mM DSP. Membranes were washed three times with 20 mM Tris (pH 7.5) supplemented with 1 mM EDTA and protease inhibitors, collected by centrifugation and solubilized in 200 µl buffer (1 % deoxycholate, 0.1 % NP40, 0.1 % SDS in 20 mM Tris, pH 7.4 supplemented with protease inhibitors). The solubilisate was incubated for 2 h at 4 °C with an immunoaffinity matrix of M 1 -specific antibodies coupled to Affigel 10. After washing, Gα q coenriched with the M 1 (raised against an antigen encompassing amino acids 231-350 of the human M 1 receptor); affinity-purified rabbit polyclonal anti-transglutaminase antibodies (raised against an antigen encompassing amino acids 1-20 of mouse transglutaminase-2); affinity-purified rabbit polyclonal anti-Gα q/11 antibodies (raised against the C-terminus of Gα q/11 ).
Immunoblotting and immunohistochemistry were routinely used to determine and confirm cross-reactivity of the antibodies with the respective proteins (10) (11) (12) Protein detection in immunoblot-Membranes were prepared by sucrose density gradient centrifugation at 4 °C followed by partial enrichment (see accompanying manuscript).
For immunoblotting analysis, protein samples were separated by SDS-PAGE under reducing conditions and supplemented with urea followed by transfer to PVDF membranes as described (11) . Affinity-purified antibodies or F(ab) 2 fragments of the respective antibodies pre-absorbed to human and mouse proteins, respectively, were used for detection of AT 2 , AT 1 receptors, and Gα q/11 . Applied antibodies were characterized in previous studies (first manuscript and references 10-13). Bound antibody was visualized by pre-absorbed F(ab) 2 fragments of enzyme-coupled secondary antibodies or by enzyme-coupled Protein A followed by enhanced chemiluminescence detection (ECL plus).
Fluorescence-activated cell sorting (FACS)
analysis-Cell surface M 1 receptors of transfected HEK cells were determined by FACS analysis using affinity-purified M 1 -specific antibodies raised against an epitope corresponding to the receptor`s amino terminal region according to standard methods (11) . Transgenic animals-Transgenic mice used in this study express human APP695 with the double mutation (K670N, M671L; APP Sw ), which was identified in a Swedish family with early onset Alzheimer`s disease (14) . Lentiviral vector production-Vector plasmids were constructed for the production of thirdgeneration lentiviruses expressing wild-type AT 2 , and AT 2 ΔCTer under control of the CMV promoter. The generation of viral particles pseudotyped with the vesicular stomatitis virus G glycoprotein was described in the first manuscript. For stereotactic injection in mice, high titer lentiviral stocks were used (> 1x10 7 transduction units/µl).
Immunohistochemistry-
For immunohistochemistry, paraffin-embedded sections (8 µm, taken at 50 µm intervals for analyses, 10-15 sections per set) were deparaffinized followed by antigen retrieval (11) . Immunohistochemical staining of AT 2 receptor was performed with F(ab) 2 fragments of preabsorbed affinity-purified polyclonal 4 antibodies (10, 11) . Immunohistochemistry with antibodies to microtubule-associated protein 2 (MAP2) was used as a marker of neuronal cell bodies and dendrites (anti-MAP2 antibodies, Sigma). DNA strand breaks were determined in situ applying TUNEL technology (Roche). All sections were imaged with a Leica DMI6000 microscope equipped with a DFC420 camera.
Cerebral injection of lentiviruses-To inhibit the formation of cross-linked AT 2 oligomers, lentivirus preparations encoding AT 2 ΔCTer were injected bilaterally into the CA1 area of 12 month-old APP Sw mice similarly as described in the first manuscript (anteroposterior -1.6 to -2.3; lateral 1; dorsoventral -1.8). The control group received injection of a control lentivirus encoding β-galactosidase or wild-type AT 2 receptor. After 1 week of recovery, mice were subjected to the stress paradigm for 4 weeks. Five weeks after the lentiviral injection, behavioral analysis, biochemical analysis and immunohistochemistry were performed. Protein expression levels of lentivirusdriven expression were routinely monitored in immunoblot with anti-AT 2 receptor antibodies (~1.8-to 2.3-fold hippocampal overexpression compared to mice injected with a control lentivirus encoding β-galactosidase). Induction of stress-The generation of Aβ was enhanced in 12-month-old APP Sw mice by four weeks of stress as described in the first manuscript. Stressed mice with a significant decrease in sucrose preference (≤ 50% of sucrose consumption compared to non-stressed controls) were included in the study. After 28 days of stress, 4h before beginning of the dark phase, brains from stressed and non-stressed APP Sw mice were removed and processed for immunoblotting, functional studies, and immunohistochemistry as described above.
Behavioral studies-We used the standard water maze task (hidden platform) to test for spatial memory (15) . Testing involved four trials per day over 10 days starting after the stress period. On the day following the 10 days of acquisition testing, memory retention was determined in a single 60-s probe trial for which the submerged platform was removed (16) . Animal experiments were reviewed and approved by the committees on animal research at the Universities of Hamburg and Cairo, and were conducted in accordance with the NIH guidelines. Statistics-Unless otherwise stated, data are expressed as mean ± s.e.m. To determine significance between two groups, we made comparisons using the unpaired two-tailed Student`s t-test. P values < 0.05 were considered significant.
RESULTS

Oxidative and transglutaminasemediated cross-linking of AT 2 receptors in vitro.
In the first manuscript we have shown that (aggregated) Aβ induces the formation of AT 2 receptor oligomers in vivo in a dosedependent manner. The formation of AT 2 oligomers in vivo is due to a two-step process of oxidative and transglutaminase-mediated cross-linking. To analyze whether reactive oxygen species (ROS) and transglutaminase were indeed sufficient to support the formation of AT 2 oligomers, we reconstituted the crosslinking in a non-neuronal in vitro system. For detection of AT 2 receptors in immunoblot we applied AT 2 -specific antibodies cross-reacting specifically with the AT 2 receptor of ~65±5 K of AT 2 receptor-transfected HEK cells (cf. accompanying manuscript; Fig.1 ). Oxidization of AT 2 receptor monomers of ~65 K could be induced in HEK cells expressing NOX-3 as a ROS-generating system leading to the appearance of an SDS-stable dimeric AT 2 form of ~130 K (Fig. 1A , lane 1). NOX-3 was chosen as a constitutively active ROSgenerating NADPH oxidase that also shows increased expression in AD patients (17) . Cross-linking of AT 2 receptors in NOX-3-expressing HEK cells was suppressed by pre-5 treatment with the antioxidant diferuloylmethane confirming involvement of ROS (Fig. 1A, lane 2) .
ROS targets tyrosine residues of proteins leading to di-tyrosine formation. Tyrosine residues of AT 2 are located at putative inter-receptor contact sites, i.e. the cytoplasmic loop connecting transmembrane helices III/IV (18) . Those inter-receptor contact sites appear crucial for ROS-mediated cross-linking of AT 2 because oxidative crosslinking was strongly diminished in a mutated AT 2 receptor lacking three tyrosines of connecting loop III-IV, AT 2 TyrAla143,148,162 ( Fig.   1B versus 1A) . ROS-dependent cross-linking assembled AT 2 for transglutaminase-mediated cross-linking because the concomitant action of ROS and transglutaminase-2 led to AT 2 receptor oligomers, whereas inhibition of transglutaminase-2 by monodansyl cadaverine prevented only the appearance of AT 2 oligomers but left the oxidized AT 2 dimers intact (Fig. 1C) . Thus, transglutaminase targeted AT 2 receptors pre-assembled by oxidative cross-linking.
Transglutaminase-dependent crosslinking of oxidized AT 2 receptors seemed to require the receptor`s carboxyl-terminus because a mutated AT 2 receptor, AT 2 ΔCTer , lacking the carboxyl terminus was not significantly cross-linked by transglutaminase-2, although oxidative dimerization was evident (Fig. 1D ). This finding is in agreement with a model of receptor oligomers identifying Cterminal residues as contact sites between dimers (18) .
ROS/transglutaminase targeted specifically the AT 2 receptor because the related AT 1 receptor appeared as a pure monomer under similar cross-linking conditions (Fig. 1E) . The specificity of transglutaminase for oxidized AT 2 receptor dimers was further analyzed by a chimeric AT 2 receptor with the carboxyl terminus of AT 1 (Fig. 1F) . This observation further confirms that the carboxyl terminus of the AT 2 receptor is required for transglutaminase-dependent cross-linking of (oxidized) AT 2 receptor dimers.
Altogether, a two-step process of oxidative and transglutaminase-dependent cross-linking leads to AT 2 oligomers in vitro (this manuscript) and in vivo (first manuscript).
AT 2 receptor oligomers sequester Gα q/11 in vitro. The biochemical similarity between in vitro formed AT 2 oligomers and in vivo detected AT 2 oligomers was further analyzed. Similarly to AD patients and mice, AT 2 oligomers of HEK cells sequestered Gα q/11 as determined by co-enrichment with Gα q/11 proteins while AT 2 monomers/dimers did not significantly interact with Gα q/11 ( The interaction with an activated Gprotein-coupled receptor is an essential part of the G-protein activation step. In agreement with this paradigm, stimulation of muscarinic M 1 receptors by carbachol strongly enhanced the interaction of M 1 receptors with Gα q as determined by co-enrichment (Fig. 2C) . The presence of AT 2 oligomers prevented the carbachol-stimulated M 1 /Gα q interaction almost entirely (Fig. 2C) . Thus, oligomeric AT 2 is capable to suppress the interaction of Gα q with an activated heterologous receptor as would be expected from its Gα q/11 -sequestering capacity.
Next, we quantified the carbacholstimulated interaction of Gα q with the M 1 receptor (~900 fmol/mg) in the presence of increasing levels of AT 2 oligomers. We chose the Gα q/11 -coupled muscarinic M 1 receptor because impaired G-protein coupling of M 1 correlates with disease severity in AD (5). Cross-linked AT 2 oligomers potently inhibited the stimulated M 1 -Gα q interaction in a 6 concentration-dependent manner with an EC 50 of ~30 fmol/mg protein (Fig. 2D) . As a control, comparable levels of the AT 2 ΔCTer mutant that was not cross-linked to oligomers under similar conditions (cf. Fig. 1D ) had no significant effect on the carbachol-stimulated M 1 -Gα q interaction (Fig. 2E) (Fig. 3A) , whereas the AT 2 ΔCTer mutant that is not cross-linked to oligomers did not significantly affect the M 1 receptor-stimulated signal under similar conditions (Fig. 3B) .
AT 2 receptor oligomers suppress Gα q/11 -stimulated signaling. We analyzed the effect of AT 2 oligomers on Gα q/11 -stimulated signaling in intact cells by measuring the Gα q/11 -stimulated activation of phospholipases C. AT 2 oligomers led to a strongly decreased inositol phosphate signal generation either under basal conditions or upon carbachol stimulation of transfected muscarinic M 1 receptors (Fig. 4A) . Inhibition of M 1 receptorstimulated signaling by AT 2 oligomers was confirmed by significantly reduced potency and efficacy of carbachol (Fig. 4B) . As a control, ROS and transglutaminase did not significantly affect M 1 -stimulated signaling in the absence of AT 2 under similar conditions (data not shown). Cell surface M 1 receptor levels as determined by fluorescence-activated cell sorting analysis with M 1 -specific antibodies were similar of HEK cells expressing dissociable AT 2 receptors or crosslinked AT 2 oligomers (Fig. 4D, panel 1 versus  2) .
Signaling stimulated by direct activation of G-proteins with GTPγS or AlF 4 -was also strongly decreased in the presence of cross-linked AT 2 oligomers while G-proteinindependent inositol phosphate generation triggered by direct activation of phospholipases C with calcium was not changed (Fig. 4A) . These findings show that AT 2 oligomers inhibit Gα q/11 -stimulated signaling.
AT 2 oligomers arrest constitutively activated Gα 11
Q209L
. AT 2 oligomers also interacted with a constitutively active mutant of Gα 11 , Gα 11 Q209L , and suppressed the inositol phosphate signal stimulated by this mutant (Fig. 4A ). This observation reveals that AT 2 oligomers act in a dominant-negative manner and induce the virtual arrest of an activated Gα q/11 protein. The dominant-negative activity of the non-dissociable oligomeric AT 2 receptor platform could account for the potent inhibition of Gα q/11 -stimulated signaling at the cell membrane which is dependent on the release of a limited number of activated Gα q/11 proteins triggered by stimulation of specific receptors.
Inhibition of calcium signaling and desensitization by AT 2 oligomers. Impaired M 1 receptor-stimulated Gα q/11 -protein activation in the presence of AT 2 oligomers was also reflected by a decreased rise in the intracellular free calcium concentration, [Ca 2+ ] i (Fig. 4C,  panels 1,2 versus 4,5) . The Gα q/11 inhibitory effect of the cross-linked AT 2 oligomers was independent of the activation of AT 2 by angiotensin II (Fig. 4C, panels 4,5) .
Activated G-proteins trigger signal generation as well as signal desensitization. To determine whether AT 2 oligomers inhibited the desensitization of the M 1 receptor, we pretreated the cells with carbachol. Carbachol pretreatment led to a significant decrease of the 7 M 1 -stimulated rise in [Ca 2+ ] i on cells expressing dissociable AT 2 receptors indicative of M 1 receptor desensitization (Fig. 4C, panel  3 versus 1,2) . In contrast, the pretreatment with carbachol did not markedly decrease the M 1 signal on cells expressing oligomeric AT 2 receptors (Fig. 4C, panel 6 versus 4,5) . Thus, AT 2 oligomers inhibit signal generation and desensitization of the Gα q/11 -coupled M 1 receptor.
Receptor desensitization is followed by receptor redistribution. Stimulation with carbachol induced prominent M 1 receptor redistribution/internalization on cells expressing dissociable AT 2 receptors (Fig. 4D,  panel 3 versus 1) . In contrast, inhibition of Gα q/11 proteins by AT 2 oligomers led to a significantly reduced carbachol-stimulated M 1 receptor redistribution (Fig. 4D, panel 4 versus 2). Together these findings show that crosslinked AT 2 oligomers arrest Gα q/11 -stimulated signaling as reflected by inhibition of different signal transduction events triggered by a prototypic Gα q/11 -coupled receptor, i.e. the muscarinic M 1 receptor.
The truncated AT 2
ΔCTer mutant suppresses AT 2 oligomerization in vitro and in vivo. We further assessed the impact of AT 2 oligomers on Gα q/11 activity and applied the truncated AT 2 ΔCTer mutant to interfere with AT 2 oligomerization. The AT 2 ΔCTer receptor when co-expressed with wild-type AT 2 prevented the transglutaminase-dependent cross-linking step accounting for AT 2 dimer/oligomer transition as determined in immunoblot with AT 2 -specific antibodies detecting specifically wildtype AT 2 receptors (Fig. 5A ). Upon inhibition of AT 2 oligomerization, the basal and M 1 receptor-stimulated Gα q/11 activation were not significantly impaired by AT 2 even in the presence of ROS and activated transglutaminase (Fig. 5B and cf. Fig. 3A ). These findings confirm that AT 2 oligomers prevent Gα q/11 activation.
To suppress Aβ-induced AT 2 oligomerization in vivo we expressed the ΔCTer led to a marked decrease of AT 2 oligomerization in the hippocampus of treated "AD mice" as determined by immunoblotting (Fig. 6A) ΔCTer by immuno-histochemistry revealed prominent neuritic/dendritic AT 2 staining in a representative treated "AD mouse" expressing AT 2 ΔCTer that was not visible in the control, i.e. a representative APP Sw mouse with stressenhanced Aβ generation and injection of a control lentivirus (Fig. 6B) . Notably, there was prominent neuritic/dendritic AT 2 staining in treated "AD mice" expressing AT 2 ΔCTer that was not visible in the controls (Fig. 6B) . Immuno-histochemistry applying MAP2-specific antibodies confirmed this observation and revealed largely intact neurites/dendrites in the injected CA1 area of mice expressing AT 2 ΔCTer , whereas there was extensive neuritic/dendritic degeneration in the control mice (Fig. 6C and cf. Fig. 7A ). These findings strongly suggest that the AT 2 ΔCTer mutant retarded the development of neurodegenerative symptoms in stressed APP Sw mice (Fig. 6C ).
In accordance with these observations, TUNEL-positive cells were barely detectable in the injected CA1 area of treated "AD mice" expressing AT 2 ΔCTer , while CA1 neurons of control mice showed prominent TUNEL labeling (Fig. 6D, right versus left panel) . Decreased symptoms of neuronal degeneration correlated with significantly reduced hippocampal transglutaminase activity (Fig.  6E ).
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Treated "AD mice" expressing AT 2 ΔCTer also displayed a marginally better performance in the CA1-dependent learning task of spatial memory acquisition and retention compared to control "AD mice" with a high load of cross-linked AT 2 receptor oligomers (Fig. 6F, G) . Together these findings strongly suggest that inhibition of AT 2 oligomerization by expression of a protein inhibitor, i.e. the AT 2 ΔCTer mutant, retarded the development of neurodegenerative symptoms in stressed APP Sw mice.
Inhibition of AT 2 oligomerization prevents G-protein dysfunction in "AD mice".
Over-expression of wild-type AT 2 receptors in "AD mice" further confirmed the involvement of AT 2 receptor(s) (oligomers) in the neurodegenerative process. While immunohistochemistry revealed intact neurons in the CA1 area of mice with AT 2
ΔCTer -dependent inhibition of oligomerization, there was profound dendritic pathology in CA1 neurons of stressed APP Sw mice overexpressing comparable levels of oligomerization-prone wild-type AT 2 receptors (Fig. 7A) . Concomitantly, over-expression of AT 2 (oligomers) led to strongly impaired M 1 receptor signaling compared to the prominent activation of Gα q/11 in mice expressing similar levels of AT 2 ΔCTer (Fig. 7B) . These findings further confirm that AT 2 (oligomers) induce Gα q/11 impairment whereas inhibition of AT 2 oligomerization by AT 2 ΔCTer prevents the development of G-protein dysfunction in transgenic mice with AD-like symptoms.
In agreement with a role of M 1 in nonamyloidogenic processing of APP (19, 20) , dysfunctional M 1 receptor-stimulated Gprotein activation of AT 2 receptor expressing mice was accompanied by a marginally decreased hippocampal α-secretase activity compared to mice with expression of AT 2 ΔCTer and intact M 1 -stimulated signaling (Fig. 7C) . Thus, the α-secretase activity of AD mice was preserved upon inhibition of AT 2 oligomerization by expression of an AT 2 mutant (this manuscript), and also upon downregulation of AT 2 (oligomerization) by RNA interference (cf. first manuscript, Fig. 6 ). Altogether, the experiments reveal that targeting of AT 2 receptor oligomers by expression of a protein inhibitor is feasible, and slows the development of neurodegenerative symptoms in transgenic mice with AD-like pathology.
DISCUSSION
G-protein dysfunction in brain of AD patients is a characteristic hallmark of clinical AD with neurodegeneration (5). In the first manuscript, G-protein dysfunction was linked to AT 2 oligomers that form in brain of AD patients and mice with AD-like symptoms. AT 2 receptor oligomers assemble in vivo by a twostep process of oxidative and transglutaminasedependent cross-linking, which is triggered consecutively by (aggregated) Aβ in a dosedependent manner (see first manuscript). To further characterize the function of AT 2 oligomers, the current study reconstituted the two-step formation of AT 2 receptor oligomers in vitro in a transfected cell system. The in vitro experiments revealed that the initial oxidative cross-linking step accounting for the formation of AT 2 receptor dimers targets specifically AT 2 with its tyrosine residues at putative inter-receptor contact sites (18) , because a mutated AT 2 receptor lacking the tyrosines of the cytoplasmic loop connecting transmembrane helices III/IV was not crosslinked by ROS. Oxidative cross-linking assembles AT 2 receptors and thereby generates the target for the second transglutaminasemediated cross-linking step leading finally to AT 2 tetramers/oligomers. Experimental evidence suggests that transglutaminasedependent cross-linking of oxidized AT 2 receptor dimers involves the carboxyl terminus of AT 2 , which is a putative contact site between receptor dimers according to the rhodopsin model (18) . Both cross-linking steps 9 are a direct consequence of aggregated Aβ and the pathogenesis of AD: Oxidative crosslinking is due to high levels of ROS triggered by aggregated Aβ (21) . The second transglutaminase-mediated cross-linking step is also linked to Aβ and the pathogenesis of AD, because cerebral microinjection of Aβ or enhanced formation of (aggregated) Aβ triggered the activation/induction of transglutaminase in mice (see first manuscript). In aggreement with a role of Aβ in inducing transglutaminase is the observation that transglutaminase activity is elevated in brain of AD patients (22, 23) .
The Aβ-induced non-dissociable oligomeric AT 2 receptor assembly seems to constitute a cellular platform that is kinetically favored to interact with activated Gα q/11 proteins. The large interface of non-dissociable AT 2 receptor oligomers could impede the rapid dissociation of activated Gα q/11 proteins upon binding. As a consequence, the activated Gα q/11 proteins are sequestered and arrested leading to decreased receptor-stimulated signaling. Mediating Gα q/11 arrest, the crosslinked AT 2 oligomers may thus contribute to the well-known Gα q/11 dysfunction in AD.
Our results suggest that the Gα q/11 -protein defect in brain of AD patients also has a pathophysiological role: (i) The G-protein defect mediated by AT 2 oligomers is causally linked to the pathogenesis of AD because it relies on aggregated Aβ-induced ROS and transglutaminase. (ii) The induction of AT 2 oligomers by aggregated Aβ was accompanied by hippocampal neurodegeneration, tau phosphorylation and neuronal loss (see first manuscript). (iii) Stereotactic inhibition of cross-linked AT 2 oligomers by expression of a mutated AT 2 receptor retarded hippocampal Gα q/11 dysfunction, and symptoms of hippocampal neurodegeneration.
Neurodegeneration and compromised neurite integrity may be a direct consequence of the AT 2 oligomer-induced Gα q/11 sequestration as evidenced with hippocampal neurons from brains lacking Gα q/11 (7, 24) . Specifically, intact Gα q/11 -mediated signaling protects (hippocampal) neurons from G 12/13 -induced neurite damage (24, 25) . Since G 12/13 -dependent signaling also links microtubules and microfilaments disorganization with tau phosphorylation (25), the AT 2 -mediated Gα q/11 impairment is likely to induce symptoms of neurodegeneration and increased phospho-tau levels via an enhanced activation of the G 12/13 pathway.
Altogether, Gα q/11 -inhibitory AT 2 receptor oligomers are formed by two sequential cross-linking steps triggered by (aggregated) Aβ. Dominant-negative AT 2 oligomers may reflect the process of ongoing Aβ-induced neurodegeneration, and also actively contribute to neuron damage.
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The initial characterization of AT 2 receptor oligomers in vivo is presented in the accompanying (first) manuscript entitled "Angiotensin II AT 2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimers`s disease". or AT 2 oligomers (+AT2 olig ; panels 4-6). As indicated, cells were co-stimulated with 100 nM of angiotensin II (Ang, panels 2,5). In the experiments of panels 3 and 6, cells were desensitized by prior stimulation with carbachol for 30 min at 37°C followed by washing steps (Cch desens.). Single experiments are representative of three independent experiments, each with similar results. D. Fluorescence-activated cell sorting analysis (FACS) of cell-surface M 1 receptors of HEK cells co-expressing dissociable AT 2 receptors (+AT2 mono ; panels 1,3) or AT 2 oligomers (+AT2 olig ; panels 2,4). In the experiments of panels 3 and 4, M 1 receptor redistribution (Redistrib.) was induced by stimulation with 1 mM carbachol for 60 min at 37 °C. Cell-surface M 1 receptors were determined by FACS using affinity-purified F(ab) 2 fragments of M 1 -specific antibodies. CTer ; ~ 150 fmol/mg) expressed in HEK cells upon ROS generation by NOX-3 and transglutaminase-2 activation (NOX-3/Tg) in the absence (-) or presence (+) of AT 2 ΔCTer suppressing the formation of cross-linked AT 2 oligomers (lane 2 versus 1). The applied antibodies were raised against a carboxyl terminal epitope of AT 2 that is lacking in AT 2 ΔCTer , and cross-react specifically with wild-type AT 2 . B. Effective Gα q/11 activation (Basal -columns 1,2; +Cch -columns 3,4) upon inhibition of AT 2 oligomerization by AT 2 ΔCTer . Activation of Gα q/11 was determined in the presence of NOX-3 and activated transglutaminase-2 (NOX-3/Tg) with membranes of M 1 receptorexpressing HEK cells co-expressing ~150 fmol/mg protein of AT 2 in the absence (-) or presence (+) of AT 2 ΔCTer (~ 150 fmol/mg protein). Data represent mean ± s.e.m., n=6 (*P < 0.001). 
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